Nathanael Smith
Foot & Ankle Surgery · Lakewood, CANPI 1760830285
Payments from drug & device makers
Across 224 payments — averaging $73.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acera Surgical, Inc.$4K
- DNE LLC$3K
- Paragon 28, Inc.$2K
- Organogenesis Inc.$1K
- Biotissue Holdings Inc.$665
- Integra Lifesciences Corporation$655
- plus $5K from 34 others
What the payments were for
- Consulting fees$3,30020%
- Travel & lodging$1,3668%
- Food & beverage$8,24250%
- Other$3,52021%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acera Surgical, Inc. | 2 | $3,640 |
| DNE LLC | 1 | $3,300 |
| Paragon 28, Inc. | 5 | $2,122 |
| Organogenesis Inc. | 33 | $1,042 |
| Biotissue Holdings Inc. | 16 | $665 |
| Integra Lifesciences Corporation | 19 | $655 |
| Mimedx Group, Inc. | 23 | $638 |
| Smith+Nephew | 26 | $636 |
| Zimmer Biomet | 9 | $527 |
| Treace Medical Concepts, Inc. | 5 | $412 |
| Amgen(2 entities) | 7 | $350 |
| Johnson & Johnson | 5 | $247 |
| Boston Scientific | 4 | $243 |
| Orthofix Medical, Inc. | 4 | $209 |
| AbbVie | 11 | $195 |
| Innovation Technologies Inc | 2 | $175 |
| Bioventus LLC | 5 | $124 |
| Stryker | 4 | $120 |
| Averitas Pharma Inc. | 4 | $118 |
| Fusion Orthopedics USA, LLC | 1 | $112 |
| Paratek Pharmaceuticals, Inc. | 7 | $111 |
| Arthrex | 1 | $108 |
| Musculoskeletal Transplant Foundation Inc. | 2 | $103 |
| Globus Medical | 3 | $91 |
| Abbott | 3 | $62 |
| Reprise Biomedical, Inc. | 1 | $55 |
| Solventum Corporation | 3 | $54 |
| Medline Industries LP | 4 | $52 |
| Merck | 2 | $39 |
| Nevro Corp. | 2 | $36 |
| Micromed Inc | 1 | $25 |
| Dynasplint Systems Inc. | 1 | $24 |
| Stimlabs LLC | 1 | $20 |
| Pacira Pharmaceuticals Incorporated | 1 | $20 |
| Novo Nordisk | 1 | $19 |
| Access Pro Medical, LLC | 1 | $19 |
| Orpyx Medical Technologies US Inc. | 1 | $18 |
| Bone Support Inc. | 1 | $15 |
| Avanos Medical | 1 | $15 |
| KCI USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Restrata Wound Matrix$3,640
- SEAL$3,300
- Product Portfolio$2,032
- INTEGRA$804
- INTEGRA DERMAL REGENERATION TEMPLATE$268
- PRIMATRIX$268
- Lapiplasty System$262
- KRYSTEXXA$253
- GRAFIX PL$220
- Stravix$220
- Irrisept$157
- CROSSTIE$126
- Nextremity MSP$115
- GENERAL VASCULAR INTERVENTION$114
- CLARIX$111
- NEOX$111
- PuraPly$111
- BIOLOGICS CONSUMABLES BONE REPAIR CELLULAR BONE GRAFTING KIT$108
- Lapidus Plate$103
How this compares
$16,428 in reported general payments places this provider in the 90th percentile of 1,126 foot & ankle surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 592 | $24,665 |
| SantylCollagenase Clostridium Hist. | 27 | $15,760 |
| Tavaborole | 29 | $9,602 |
| Ciclopirox | 228 | $5,231 |
| Clotrimazole | 170 | $5,230 |
| Diclofenac Sodium | 107 | $2,394 |
| Econazole Nitrate | 41 | $2,142 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 18 | $2,038 |
| Terbinafine Hcl | 77 | $1,701 |
| CiclopiroxCiclopirox Olamine | 36 | $1,502 |
| Ammonium Lactate | 101 | $1,334 |
| Lidocaine | 25 | $1,005 |
| Nitroglycerin PatchNitroglycerin | 18 | $900 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 69 | $425 |
| Gabapentin | 52 | $305 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $636 | $15,76027 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,126 foot & ankle surgery providers in California.
Other foot & ankle surgery in Lakewood
- John ZimmermanBakersfield$4.6M
- Eric GizaSacramento$3.7M
- Thomas HarrisPasadena$3M
- Felix SigalLos Angeles$2.2M
- Thomas ChangSanta Rosa$2.1M
- Michael CoughlinSan Francisco$1.6M
- Vladimir ZeetserEncino$677K
- Jason NowakRedding$526K
- Candice BradyCamarillo$462K
- Andrew HsuOrange$456K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.